Genmab — Earnings Release 2010

Apr 28, 2010

News Details

Ad-hoc | 28 April 2010 13:23

Arzerra First Quarter 2010 Net Sales Figures

Genmab A/S /

28.04.2010 13:23

Dissemination of a Adhoc News, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Summary: Net sales of Arzerra(r) for the first quarter of 2010 were approximately
DKK 42 million, with an expected royalty payment to Genmab of DKK 8 million.

Copenhagen, Denmark; April 28, 2010 - Genmab A/S (OMX: GEN) announced today
that the U.S. net sales for Arzerra (ofatumumab) during the first quarter of
2010 were approximately DKK 42 million (approximately USD 7.5 million). Under
the terms of the collaboration with GlaxoSmithKline (GSK) Genmab expects to
receive a royalty payment of approximately DKK 8 million (approximately USD 1.4
million).

'We are pleased that Arzerra offers a new treatment option for patients with
chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab,' said
Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab 'likewise we are
looking forward to this option being available in the EU as well'.

Arzerra was granted accelerated approval by the FDA in October, 2009, for the
treatment of patients in the U.S. with chronic lymphocytic leukemia (CLL) that
is refractory to fludarabine and alemtuzumab. Arzerra was launched by GSK in
mid-November, 2009. In April 2010, a conditional marketing authorization for
the treatment of chronic lymphocytic leukemia in patients who are refractory to
fludarabine and alemtuzumab was granted by the EU Commission.

About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery and development teams are using cutting-edge
technology to create and develop products to address unmet medical needs. Our
primary goal is to improve the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
section 'Risk Management' in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.

Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax-EGFr?;
HuMax-IL8?; HuMax-TAC?; HuMax-HepC?; HuMax-CD38?; HuMax-CD32b?; HuMax-TF?;
HuMax-Her2?; HuMax-VEGF?; HuMax-Wnt; HuMax-cMet? and UniBody(r) are all
trademarks of Genmab A/S. Arzerra(r) is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

Stock Exchange Release No. 16/2010

News Source: NASDAQ OMX

28.04.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Genmab A/S

          Denmark

Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of News DGAP News-Service

---